Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects

Gastroenteritis Clinical Trial

Official title:

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects Aged 18-59 Years

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05805618
• Other study ID #: KH-CT-002-01
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: July 1, 2024
• Est. completion date: November 1, 2024

Study information

• Verified date: November 2023
• Source: Syneos Health
• Contact: Fanny Hou, PM
• Phone: +86 18502191682
• Email: fanny.hou[@]syneoshealth.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and immunogenicity of different dose levels of the Recombinant Norovirus Hexavalent Vaccine in healthy subjects aged 18-59 years given three doses of the vaccine at 28-day intervals.

Description:

It is planned to enroll healthy subjects and adopt a 3-dose vaccination schedule (day 0 to day 56) of intramuscular injections of study vaccines in the deltoid muscle of the upper arm of subjects on day 0, day 28 and day 56, respectively. The subjects will sequentially enter into the low and high dose groups by stages, with approximately 30 subjects in each group (test group:control group = 2:1) and approximately up to 60 subjects in total. At least half of the subjects are Chinese in the two cohorts respectively

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: November 1, 2024
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

1. Aged 18-59 years (inclusive);

2. Subjects with a body mass index ( 18 kg/m2 and 35 kg/m2;

3. Capable and willing to give informed consent prior to any study-specific activities/procedures;

4. Subjects who are able to comply with the requirements of the clinical study protocol to complete the study;

5. Subjects who haven't been vaccinated or haven't plan to be vaccinated with other vaccines (including live attenuated vaccines, non-live vaccines, and novel coronavirus vaccines) within 14 days before the first dose of study vaccines;

6. Subjects who are clinically determined to be healthy by the investigator after being inquired about their medical history and relevant physical examinations;

7. Female subjects who are not breastfeeding; all subjects who have no childbearing plan or sperm/egg donation plan from ICF signing to 6 months after the completion of the vaccination series and agree to take effective contraceptive measures (See the appendix 3) from 4 weeks prior to the first dose to 6 months after the completion of the vaccination series.

Exclusion criteria for the first vaccination dose

1. Subjects with positive COVID-19 test by PCR for nasopharyngeal or oropharyngeal swabs (nasopharyngeal swabs are preferred) on the day of the first dose vaccination;

2. Subjects who have previously participated in a clinical study of any type of norovirus vaccines within the past year before enrollment in this study;

3. Subjects with a history of chronic gastrointestinal disorder or having gastroenteritis that required treatment (for example, seek medical advice, etc.) within the past year before screening; or subjects have diarrhea, vomiting, or other digestive system conditions before 2 weeks of the first dose vaccination;

4. Subjects have cancer or have a history of cancer within 5 years before screening;

5. Subjects with the following conditions: (1) serious congenital malformations, serious developmental disorders, serious genetic defects, serious malnutritions, etc.; (2) thrombocytopenia, coagulation disorder or receipt of anticoagulant therapy, and other contraindications to intramuscular injections; (3) congenital or acquired immunodeficiency or receipt of immunosuppressant therapy (excluding topical treatment, surface treatment for acute non-complicated dermatitis, spray treatment for allergic rhinitis, ICS use for asthma treatmen, etc.) within 6 months; (4) history of infectious diseases, such as tuberculosis; (5) history or family history of convulsions, epilepsy, encephalopathy; (6) asplenia, functional asplenia, and asplenia or splenectomy due to any cause; (7) serious cardiovascular diseases (pulmonary heart disease and pulmonary edema), serious liver and kidney diseases, type I diabetes, celiac disease, autoimmune diseases, etc.; (8) use of medications within the timeframes specified in Section 6.5.2 ;

6. Subjects with a clinicallly significant history of serious hypersensitivity to any component of study vaccines, including adjuvant components and yeast, such as allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, and local allergic necrotic reaction (Arthus reaction); a history of serious adverse vaccine or drug reactions, such as allergy, urticaria, skin eczema(small, local rashes on a single body part are permitted), dyspnea, and angioedema;

7. Subjects with abnormal and clinically significant results of laboratory tests at the discretion of Investigator, such as hematology, serum chemistry, and urinalysis;

8. Subjects with abnormal and clinically significant ECG results up to the Investigator's discretion at screening;

9. Females of childbearing potential with positive serum pregnancy test results;

10. Subjects who are positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody, or anti-treponema pallidum (anti-TP) antibody at screening;

11. Subjects with hypertension (systolic blood pressure 140 mmHg and/or diastolic blood pressure 90 mmHg) or hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure 40 mmHg) (regardless of medication use) in the physical examination before enrollment;

12. Subjects with fever (oral temperature = 37.5 °C) on the day of vaccination with study vaccines or within 72 h before vaccination;

13. Subjects who have donated blood or lost blood (= 400 mL) or received blood transfusion or used blood products within 30 days before signing the ICF or plan to donate blood during the study(from the first vaccination dose to 3 months after the completion of the vaccination series);

14. Subjects who have undergone surgery within 3 months before signing the ICF or plan to undergo surgery (including cosmetic surgery, dental surgery, and oral surgery(excluding tooth filling, protaper and tooth extraction)) during the study (from the first vaccination dose to 3 months after the completion of the vaccination series);

15. Smoking more than 10 cigarettes per week within 3 months prior to screening;

16. History of alcohol abuse within 1 year prior to screening, or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%);

17. History of drug abuse within 1 year prior to screening, or recreational use of soft drugs (such as marijuana) or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, codeine and amphetamine derivatives) within 1 month prior to screening;

18. Subjects with positive tests for drugs of abuse (including Amphetamines (AMP), Methamphetamines (MET), Methadone (MTD), Barbiturates (BAR), Benzodiazepines (BZO), Cocaine (COC), Opiates (OPI), Methyl enedioxy methamphetamine (MDMA) , Phencyclidine (PCP), Tetrahydrocannabinol (THC)) and alcohol breath test;

19. Subjects with tattoos, scars or skin defects covering the deltoid muscle who are not suitable to participate in the study up to the investigator's discretion;

20. Subjects who cannot tolerate venipuncture or have a history of fear of needles or hemophobia;

21. Subjects who are not suitable to participate in the study as determined by the investigator .

Related Conditions & MeSH terms

• Gastroenteritis

Intervention

Biological:
• Recombinant Norovirus Hexavalent Vaccine
To prevent acute gastroenteritis caused by norovirus of genotypes GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17

Other:
• Matching Placebo
matching placebo for Recombinant Norovirus Hexavalent Vaccine / KH002

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Syneos Health	Chengdu Kanghua Biological products Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of solicited AEs within 7 days after each vaccination dose.	Safety will be assessed through 7 days after vaccination (including the day of vaccination) via collection of solicited AEs. The solicited AEs include local AEs (injection site: pain,tenderness, induration,swelling,erythema,pruritus)and systemic AEs (Headache, Fatigue,Myalgia,Arthralgia,Vomiting, Diarrhea, Fever).	7 Days
Primary	Incidence of unsolicited AEs within 28 days after each vaccination dose	Unsolicited AEs are AEs other than those designated as solicited AEs, and also include eponymous solicited AEs that occur after the solicitation period. Unsolicited AEs mainly include any AEs that have been reported by the subjects, learned from interrogation or observed by the investigator during the study visits, or discovered during review of medical records or original files. the incidence of unsolicited AEs within 28 days after each dose of the study vaccine will be calculated.	28 Days
Primary	Incidence of AEs related to serum chemistry, hematology, and urinalysis parameters in all subjects on day 4 after each vaccination dose and on day 14, day 42 after the first dose	The number of participants with any markedly abnormal standard safety laboratory values (serum chemistry,hematology or urinalysis) collected.	42 days
Primary	SAE, MAAE in all subjects within 12 months after the completion of the vaccination series.	The subjects will also be monitored for SAEs, MAAEs from the first dose to 12 months after the completion of the vaccination series.	12 Months
Secondary	GMT of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP HBGA (BT50)	GMT is geometric mean titer. HBGA is Histo-blood group antigen. Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination (up to Day 421)	12 Months
Secondary	GMFR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP HBGA	GMFR is geometric mean fold rise. Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination (up to Day 421)	12 Months
Secondary	SCR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP HBGA	SCR is Seroconversion rate. Seroconversion is defined as: For the subject whose antibody titer is below the lower limit of quantification before vaccination, the antibody titer is increased to the lower limit of quantification or above after vaccination; for the subject whose antibody titer is at the lower limit of quantification or above before vaccination, the antibody titer is increased at least 4-fold after vaccination. Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	GMT of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP Pan-Ig	predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	GMFR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP Pan-Ig	Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	SCR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP Pan-Ig	Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	GMT of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP IgA	Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	GMFR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP IgA	Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	SCR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP IgA	Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	GMT of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP IgG	Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	GMFR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP IgG	predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	SCR of Serum Anti-norovirus GI.1 and GII.2, GII.3, GII.4, GII.6, GII.17 VLP IgG	Predose 0 and 7, 14, 28 days after the first and second dose, and 7, 14, 28 days, 3, 6, 12 months after completion of full vaccination	12 Months
Secondary	Norovirus-specific T-cell IFN-?,IL-2, IL-4 and IL-10 levels In the high dose group.	Predose 0 and 7, 28 days after completion of full vaccination	28 Days